Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« The Tiniest Doors Begin to Open | Main | Remind Me Not to Do This Again »

September 8, 2005

Muraglitazar's Turn

Email This Entry

Posted by Derek

There's a lot of metabolic disease news this week from the FDA. We'll get to the inhaled insulin decision next week, but I thought I'd try to catch the next one before it happens. On Friday they're reviewing the first PPAR alpha-gamma ligand to make it to the regulatory approval stage, Bristol-Meyers Squibb's unmelodious "Pargluva" (muraglitazar), which sounds more like a disease than a drug. This is a therapeutic class that everyone had great hopes for a few years ago, with most of the big players competing at full speed. In theory, this combination should help with insulin sensitivity, cholesterol, and triglycerides all at the same time, which you'd think would be just what an overweight type II diabetic patient (and there are many) might need.

But development of these compounds has been a nightmare, with bad and unexpected toxicity cropping up deep in the late-phase work. BMS (and their late-arriving partner Merck) managed to get past those rapids and through clinical trials. But their drug shows a side effect that all PPAR-gamma drug programs have had to worry about, namely edema.

They also seem to have some (perhaps related) worries about cardiovascular events, which are broken out into completely separate categories in the FDA briefing document (big PDF). That document, whopper thought it is, is worth a look if you want to see what it's like to decide whether to approve a new drug or not. I wouldn't like to have to explain it all to a lay jury, that's for sure. No doubt a few whoops and hollers, along with the occasional choked tearful expression, would help.

By my reading, the cardiovascular event profile of the drug subjects looks slightly but noticeably worse than that of the placebo group. There are plenty of possible extenuating factors, and the number of patients involved is small, but I think that this is going to be a problem for the companies during the FDA hearing. Here's the list of questions the FDA has proposed for discussion (PDF again), and you can see that edema and cardiovascular safety loom large. I can't predict which way this one is going to go, and neither can anyone else. But post-COX-2 is a bad time to be coming to the FDA with possible low-level cardiac risks in your clinical data. . .

By the way, with thousands of people involved in the clinical studies, there are bound to be some. . .unplanned adverse events. I quote without comment from the briefing document linked to above, just in case you thought (for some odd reason) that running clinical trials was easy. . .

"Subject CV168021-29-21 was a 44-year old white maile with a 3-year history of diabetes and history of overweight, hypercholesterolemia and impotence. On study day 29 the subject died as the result of a gun shot wound.

Subject CV-168006-5-3 was a 62-year old white female with a history of hypertension, smoking, and alcohol use. On study day 112 she died in a motor vehicle accident. Her car was stopped at a light when struck by a truck. The investigator considered the event not likely related to study drug."

Yes, one would, on the whole, conclude that it wasn't . . .

Comments (7) + TrackBacks (0) | Category: Clinical Trials | Diabetes and Obesity


COMMENTS

1. chemist on September 9, 2005 8:37 AM writes...

While its tempting to make summary statements regarding the deaths resulting form automobile accidents and gunshot wounds, the reality is that determining that these are not drug related is more difficult than one might initially imagine. For example, suicidal and other abnormal mental behaviors need to be excluded as possibly being drug induced.

Permalink to Comment

2. Derek Lowe on September 9, 2005 9:18 AM writes...

True enough, but being hit by a truck while stopped at a light doesn't sound like impaired reflexes. Muraglitazar's structure makes it quite unlikely to penetrate the CNS, although I haven't seen the PK data on that yet.

Permalink to Comment

3. John Johnson on September 9, 2005 9:41 AM writes...

Analyzing adverse event (AE) relatedness is one of those things that makes biostatisticians like me have their own AEs (usually something on the order of major seizure). On the one hand, there is the point of view that all relatedness data is BS and so all AEs are considered "related." Yes, even the gunshot wound and the auto accident, and the plane crash, meteors striking, whatever. Of course, there is an attempt to define relatedness in terms of when symptoms disappear and reappear (and removal of drug and rechallenge, ad nauseum). Despite this, there are some SOBs that will ignore relatedness data.

Now the real kicker is that the serious AEs come into the data entry system twice: once because of expedited reporting/safety committee monitoring and one because of standard, run of the mill case report form entries that are entered into the clinical database. And they'd better match, and this takes a lot of effort. And then when they come to us, something weird always falls out, so it's back and forth, back and forth. Because people's bodies do the darndest things. And when it's unplanned (always a bad thing in Phase III), you gotta file a safety update, unblind the patient's data (not a good thing), assess the impact of this on the probable conclusions and interpretations of the study's analysis, and on and on.

You oughtta pick up a book on clinical trials sometimes (like Fundamentals of Clinical Trials by Friedman et al.) sometime and look at the section on AEs. It starts not to look pretty, and actually working with the damned things is much much harder.

Permalink to Comment

4. Sigivald on September 9, 2005 1:36 PM writes...

Wasn't Muraglitazar a Babylonian king in the Old Testament?

Permalink to Comment

5. Linkmeister on September 9, 2005 2:39 PM writes...

"The investigator considered the event not likely related to study drug."

Who knew that investigators (or report writers) had such a dry sense of humor?

Permalink to Comment

6. Timothy on September 12, 2005 8:27 AM writes...

I can see the headlines now, "New drug causes gunshot wounds, film at 11".

Permalink to Comment

7. Sebastian Holsclaw on September 14, 2005 11:07 AM writes...

But are they certain that taking the drug doesn't attract trucks? :)

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Did Pfizer Cut Back Some of Its Best Compounds?
Don't Optimize Your Plasma Protein Binding
Fluorinated Fingerprinting
One of Those Days
ChemDraw Days
Incomprehensible Drug Prices? Think Again.
Proteins Grazing Against Proteins
Sulfates, And What They Can Make